Victorian Government opens ‘Investing in Manufacturing Technology’ Grants
28 June, 2012 by AusBiotechGrants of up to $250,000 are available under the Investing in Manufacturing Technology (IMT) grants scheme to assist businesses to purchase and integrate new technologies into their business.
Stable antibody breakthrough solves sticky biotech problem
28 June, 2012 by Tim DeanResearchers at the Garvan Institute have developed a new technique to produce antibodies that are resistant to clinging together into a sticky mess, solving a longstanding technical problem in biotech.
Bell Potter downgrades QRxPharma after FDA shock
28 June, 2012 by Tim DeanBell Potter Securities has reset its optimistic target valuation of QRxPharma from $3.69 to $1.26 after the FDA failed to approve the company’s MoxDuo IR.
BioDiem licenses hepatitis vaccine tech from UC
27 June, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has signed its second vaccine technology licensing deal this week, securing exclusive rights to IP with potential applications in hepatitis B and D.
QRxPharma shares tumble after FDA knockback for MoxDuo IR
27 June, 2012 by Tim DeanShares down over 50% after the FDA requests more information on safety and efficacy from QRxPharma on its MoxDuo IR before granting regulatory approval.
Final days for early bird for AusBiotech 2012
26 June, 2012 by AusBiotechRegister in the next four days (by 30 June) for the industry event of the year and save $250 with early bird rates.
Feature: Raising the bar on IP
26 June, 2012 by Tim DeanFrom 15 April 2013 patents will be significantly harder to secure in Australia. We look at the implications of the Raising the Bar bill on Australian life science organisations.
BioDiem closes dengue fever deal
25 June, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and ANU have finalised the terms of the exclusive licensing deal covering a vaccine technology for diseases such as dengue fever.
CogState signs licensing deal with Merck Canada
25 June, 2012 by Dylan Bushell-EmblingCogState (ASX:CGS) has signed the first of a planned series of licensing deals to have its tests sold to GPs for the detection of neurodegenerative conditions.
STA to bring new CDI treatment to A/NZ
22 June, 2012 by Dylan Bushell-EmblingSpecialised Therapeutics Australia (STA) has secured a deal to launch a new therapy for the colostrum difficile “superbug” in Australia and New Zealand.
Market moves: CSL buyback hits $600m
21 June, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) has now repurchased close to $600 million worth of its own shares, under a buyback program which commenced in October last year.
Mayne clears hurdle to SUBACAP approval in EU
21 June, 2012 by Dylan Bushell-EmblingMayne Pharma (ASX:MYX) is back on track to gaining marketing approval from the EMA for its SUBACAP fungal infection treatment, after its application was temporarily derailed by UK regulators.
World’s top agbiotech conference to visit Down Under
21 June, 2012 by AusBiotechThe world’s leading agricultural biotechnology event, ABIC (Agricultural Biotechnology International Conference) 2012, is coming to our region in September with the annual event to be held in Rotorua, New Zealand, and hosted by NZBIO with the support of AusBiotech.
Virus traces in Fluvax blamed for risk in children
21 June, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) unit CSL Biotherapies has tentatively blamed the particulars of the manufacturing process for the adverse reactions to its Fluvax influenza vaccine in some young children in 2010.
BIO 2012 biotech profile: Bionomics
20 June, 2012 by Dylan Bushell-EmblingBionomics recently captured headlines with its spectacular deal with Ironwood Pharmaceuticals for its anti-anxiety compound, BNC210. But the South Australian biotech has even more tricks up its sleeve.
